SPARCSun Pharma Advanced Research Company Ltd.

    Sun Pharma Advanced Research Company Ltd: results and news

    Every Sun Pharma Advanced Research Company Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings.

    1 article · pharmaceutical research and development · Latest 2 Nov 2026

    Two glass laboratory flasks standing in cork rings

    SPARCSun Pharma Advanced Research Company Ltd.

    Sun Pharma Advanced Research Company Q2 FY27 Results: Consolidated Net Loss ₹24.39 Crore on Total Income of ₹53.65 Crore

    Sun Pharma Advanced Research Company (NSE: SPARC) reported consolidated total income of ₹53.65 crore and a net loss of ₹24.39 crore for the quarter ended 30 Sep 2026, as stated in its filing of 02 Nov 2026. Standalone total income was the same at ₹53.65 crore, with a net loss of ₹24.58 crore.

    • Earnings
    • pharmaceutical research and development

    Blacklitt Research3 min read